Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: golfer72 who wrote (1445761)	3/11/2024 4:24:20 PM
From: Qone0	2 Recommendations Recommended By Eric Tenchusatsu Respond to of 1573430

Deal with it. Moderna, BioNTech Stocks Rise on New mRNA Possibilities — WSJ Mar 11, 202414:42 EDT BNTX+5.50% MRNA+8.71% By Jonathan D. Rockoff The pandemic validated the disease-fighting prowess of mRNA vaccines. Shares of Moderna and BioNTech rose on Monday after two tantalizing morsels hinted at their potential for attacking cancer. Cancer treatment is one of the pharmaceutical industrys biggest, most lucrative markets. Its been a prized target of biotechs like Moderna and BioNTech, which have sought to extend their messenger RNA technology beyond infectious diseases like Covid-19 or RSV. Moderna and Merck launched a Phase 2/3 study (https://clinicaltrials.gov/study/NCT06295809?intr=V940&rank=3) of Mercks Keytruda with Modernas experimental skin-cancer vaccine, according to a new posting on the governments clinicaltrials.gov. Jefferies analyst Michael Yee said the initiation of such an expensive trial indicates the companies confidence in the program. Another titillating sign of mRNAs potential advance came from BioNTech, which said it plans to present (https://investors.biontech.de/news-releases/news-release-details/biontech-present-clinical-data-updates-personalized-mrna-based) pancreatic-cancer data from a study evaluating a vaccine it is developing with Roches Genentech at the American Association for Cancer Researchs meeting in April. Both tidbits say very little, but they suggest enough to have spurred shares of Moderna and BioNTech higher. Yee said the two companies had been shorted, but that the potential of the latest disclosures is drawing back investors. Moderna rose 9.2%, while BioNTech was up 5.4%. NOTE: In-line links reference additional content of interest chosen by the WSJ news team. This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). https://www.siliconinvestor.com/readmsg.aspx?msgid=33379231&srchtxt=medical%20breakthrough